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April 4, 2006:1502–5reduced LVEF who can be carefully monitored for preserved renal function and normal
potassium concentration. Creatinine should be less than or equal to 2.5 mg/dL in men or less
than or equal to 2.0 mg/dL in women and potassium should be less than 5.0 mEq/l. (Under
circumstances where monitoring for hyperkalemia or renal dysfunction is not anticipated to be
feasible, the risks may outweigh the benefits of aldosterone antagonists.) (Level of Evidence: B)”
8. On page 1128, CLASS IIA recommendation 3, the level of evidence should be changed from A to
B to read, “The addition of a combination of hydralazine and a nitrate is reasonable for patients with
reduced LVEF who are already taking an ACEI and beta-blocker for symptomatic HF and who
have persistent symptoms. (Level of Evidence: B)”
9. On page 1129, right column, second paragraph, third line, the word “small” should be deleted.
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In the article, “ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic
Heart Failure in the Adult: A Report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines (Writing Committee to Update the 2001
Guidelines for the Evaluation and Management of Heart Failure),” by Hunt et al., which appeared
in the September 20, 2005, issue of the journal (J Am Coll Cardiol 2005;46:e1–82), the following
clarifications are needed:
1. In Figure 1, under therapy for Stage B, the following text should be added below the listings for Drugs:
igure 1. Stages in the development of heart failure/recommended therapy by stage. FHx CM indicates family history of cardiomyopa-
hy; ACEI, angiotensin converting enzyme inhibitor; and ARB, angiotensin receptor blocker.“DEVICES IN SELECTED PATIENTS: Implantable defibrillators.” See revised figure below.
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April 4, 2006:1502–52. In Table 3, the legend defining HF is incorrect. The words “and asymptomatic left ventricular
dysfunction” should be deleted. Also, the definition of Asymptomatic LVSD (asymptomatic left
ventricular systolic dysfunction) should be added. Thus, the table legend should read, “Asymp-
tomatic LVSD indicates asymptomatic left ventricular systolic dysfunction; CV Risk, reduction in
future cardiovascular events; DN, diabetic nephropathy; H, hypertension; HF, heart failure; Post
MI, reduction in heart failure or other cardiac events following myocardial infarction.”
3. On page e19, left column, final paragraph, the word “no” should be deleted before “HF” in the
seventh line to read, “The aldosterone antagonist eplerenone has been shown to reduce morbidity
and mortality in a population of patients with low EF and HF after MI that has already been treated
with ACEIs and beta-blockers (98, 99).”
4. In Table 4, a dagger should be added after “Potassium-sparing diuretics.” In the legend, the
following definition should be added: “†Eplerenone, although also a diuretic, is primarily used in
chronic heart failure as a suppressor of the renin-angiotensin-aldosterone system.”
5. On page e21, the following Class I recommendation should be added after recommendation 6: “7.
Maximal exercise testing with or without measurement of respiratory gas exchange is recom-
mended to facilitate the prescription of an appropriate exercise program for patients presenting with
HF. (Level of Evidence: C)”
6. On page e21, current recommendations 7, 8, 9, 10, 11, and 12 should be renumbered 8, 9, 10, 11,
12, and 13 to accommodate the new recommendation 7.
7. On page e21, in current recommendation 11, 6th line, “0.12 ms” should be changed to “120 ms.”
8. On page e21, in current recommendation 12, first line, the word “reasonable” should be replaced with
the word “recommended.”
9. On page e22, Class IIa recommendation 3, the level of evidence should be changed from A to B.
igure 1. Stages in the development of heart failure/recommended therapy by stage. FHx CM indicates family history of cardiomyopa-
hy; ACEI, angiotensin converting enzyme inhibitor; and ARB, angiotensin receptor blocker.10. On page e28, right column, the second sentence in the paragraph that begins after the heading
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April 4, 2006:1502–5“Recommendations Concerning ARBs” should be changed to cite the CHARM-Alternative trial,
reference 223, instead of the CHARM-Preserved trial, reference 235.
11. On page e40, Section 4.3.1.4.7. NESIRITIDE, first paragraph, two references are cited that should be added
to the reference list.
423a. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for
decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005;293:1900–1905.
423b. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in
patients with acutely decompensated heart failure. Circulation 2005;111:1487–1491.
12. On page e40, Section 4.3.1.4.7. NESIRITIDE, second paragraph, first sentence, the word
“chronic” should be added before “HF” to read, “They are currently under investigation
as adjunctive therapy, administered on an intermittent outpatient basis, for advanced
chronic HF.”
The corrected version of this article is available online at http://www.onlinejacc.org.
doi:10.1016/j.jacc.2006.02.030
